Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Acquisitions & Divestments: 2023-2025

Historic Change in Acquisitions & Divestments for GeneDx Holdings (WGS) over the last 2 years, with Sep 2025 value amounting to $7.2 million.

  • GeneDx Holdings' Change in Acquisitions & Divestments fell 55.34% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year increase of 92.13%. This contributed to the annual value of $41.1 million for FY2024, which is 131.13% up from last year.
  • As of Q3 2025, GeneDx Holdings' Change in Acquisitions & Divestments stood at $7.2 million, which was down 43.25% from $12.8 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Change in Acquisitions & Divestments peaked at $16.7 million during Q3 2023, and registered a low of $1.1 million during Q4 2023.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $12.8 million (2025), whereas its average is $10.3 million.
  • In the last 5 years, GeneDx Holdings' Change in Acquisitions & Divestments surged by 1,364.09% in 2024 and then tumbled by 55.34% in 2025.
  • Over the past 3 years, GeneDx Holdings' Change in Acquisitions & Divestments (Quarterly) stood at $1.1 million in 2023, then soared by 1,364.09% to $16.1 million in 2024, then tumbled by 55.34% to $7.2 million in 2025.
  • Its Change in Acquisitions & Divestments was $7.2 million in Q3 2025, compared to $12.8 million in Q2 2025 and $13.9 million in Q1 2025.